FibroGen, Inc.
FibroGen, Inc. (FGEN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · FGEN · as of Jun 9, 2026
Key Statistics
Explore FibroGen, Inc. Data
fgen stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 14 · Buy rate: 35.7%
The FGEN analyst consensus is Hold, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $28.00, representing +208.71% upside from the current price of $9.07.
Competitors & Peers
fgen competitorsFGEN
ALGS
ATNM
CELU
KZR
MRSNStock Performance
Full HistoryAbout FibroGen, Inc.
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Am…
what is fibrogen, inc. · fgen stock overview · fibrogen, inc. company profile · who is fibrogen, inc. ceo · fgen NASDAQ · fibrogen, inc. headquarters · fibrogen, inc. business segments
About Stock Overview & Key Data
FibroGen, Inc. (FGEN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 14, 2014. As of the latest trading session, FGEN stock price is $9.07, with a market capitalization of $36.7M. The stock has returned -23.72% over the past 12 months and -0.98% year-to-date.
According to 14 Wall Street analysts, the consensus rating for FibroGen, Inc. stock is Hold, with an average 12-month price target of $28.00. In fiscal year 2025, FibroGen, Inc. reported revenue of $6.4M and net income of $183.5M. For detailed data — including FibroGen, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, FibroGen, Inc. (FGEN) stock price is $9.07. The stock is traded on NASDAQ under the ticker symbol FGEN. The 52-week range is $4.85 – $21.95.